trial

First Episode Schizophrenia and Cannabis-Related Disorder Study

NCTId NCT00573287
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 14 (actual)
Sponsored by Dartmouth-Hitchcock Medical Center
Primary completion 2010-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
14 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2006-06
Primary completion
2010-12
Eligibility
ALL · 17 Years · 45 Years

Interventions & indications

Drugs
ClozapineRisperidone

Sponsors

Dartmouth-Hitchcock Medical CenterLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

2
Alan I. Green, MDPrincipal Investigator
Doug Noordsy, MDStudy Director

Sites

5 total
Concord, United StatesLebanon, United StatesLebanon, United StatesManchester, United StatesNashua, United States

Facts & assertions

4 sourced
Enrollment
14
Phase
NA
Primary Completion Date
2010-12
Status
COMPLETED
relationships
The graph out of here
drug
Clozapine
drug
Risperidone
drug
lead_sponsor
Dartmouth-Hitchcock Medical Center
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Psychotic Disorders
indication
Psychotic Disorders
indication
Marijuana Abuse
indication
investigator
Alan I. Green, MD
person
Doug Noordsy, MD
person